{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antipsychotics&page=2",
    "query": {
      "intervention": "Antipsychotics",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antipsychotics&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T12:25:09.272Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03818256",
      "title": "A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antipsychotic-induced Weight Gain (AIWG)"
      ],
      "interventions": [
        {
          "name": "Miricorilant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 71,
      "start_date": "2019-12-04",
      "completion_date": "2022-07-06",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 27,
      "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03818256"
    },
    {
      "nct_id": "NCT02034253",
      "title": "Glutamate, Brain Connectivity and Duration of Untreated Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia",
        "Psychosis",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "17 Years to 35 Years"
      },
      "enrollment_count": 134,
      "start_date": "2014-01",
      "completion_date": "2018-11",
      "has_results": false,
      "last_update_posted_date": "2019-01-22",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02034253"
    },
    {
      "nct_id": "NCT00373672",
      "title": "Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "armodafinil (Nuvigil)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 58,
      "start_date": "2006-08",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00373672"
    },
    {
      "nct_id": "NCT00802100",
      "title": "Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Perphenazine",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Benztropine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 21,
      "start_date": "2008-12",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-02-08",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 13,
      "location_summary": "Colton, California • Palo Alto, California • New Haven, Connecticut + 10 more",
      "locations": [
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00802100"
    },
    {
      "nct_id": "NCT00156637",
      "title": "A Study of Strategies to Improve Schizophrenia Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Team-Based Quality Improvement Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Opinion Leader Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Team Based Quality Improvement",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 106,
      "start_date": "2005-06",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 4,
      "location_summary": "Fayetteville, Arkansas • No. Little Rock, Arkansas • Dayton, Ohio + 1 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "No. Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00156637"
    },
    {
      "nct_id": "NCT01125267",
      "title": "Promoting Adherence to Treatment in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "multifamily group-adherence",
          "type": "BEHAVIORAL"
        },
        {
          "name": "multifamily group-standard",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 174,
      "start_date": "2003-04",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2010-05-18",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 1,
      "location_summary": "Granada Hills, California",
      "locations": [
        {
          "city": "Granada Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01125267"
    },
    {
      "nct_id": "NCT00399776",
      "title": "Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adolescent Depression"
      ],
      "interventions": [
        {
          "name": "Bone Density Test",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Creighton University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 60,
      "start_date": "2006-10",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2011-08-04",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00399776"
    },
    {
      "nct_id": "NCT03495024",
      "title": "Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Tobacco Smoking",
        "Tardive Dyskinesia",
        "Parkinsonism"
      ],
      "interventions": [
        {
          "name": "Varenicline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corporal Michael J. Crescenz VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2019-01-01",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03495024"
    },
    {
      "nct_id": "NCT02087579",
      "title": "Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psychotic Disorders",
        "Schizophrenia",
        "Bipolar Disorder",
        "Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone, LAI",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Risperidone, oral formulation",
          "type": "DRUG"
        },
        {
          "name": "Risperidone, LAI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 305,
      "start_date": "2014-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-10-29",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 6,
      "location_summary": "Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hoffman Estates",
          "state": "Illinois"
        },
        {
          "city": "Cedarhurst",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02087579"
    },
    {
      "nct_id": "NCT06433635",
      "title": "Sequential Multiple Assignment Randomized Trial for Bipolar Depression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar I Disorder",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Cariprazine",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole/Escitalopram combination",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        },
        {
          "name": "Lurasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2726,
      "start_date": "2024-10-01",
      "completion_date": "2030-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-09-13T12:25:09.272Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Belmont",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06433635"
    }
  ]
}